Navigation Links
Alchemia Reports Preliminary Positive Efficacy Data From HyCAMP,Phase II Trial

fter the welfare of the patients and diligently collected the data for analysis in this trial.

    ENQUIRIES: Dr. Tracie Ramsdale

    Chief Executive Officer

    Alchemia Limited

    Tel: +61-7-3340-0200


    RELEASED BY:

    Ms Anna Whybird

    Phillips Group

    Tel: +61-7-3230-5000

About HyACT

HyACT(TM) is a proprietary delivery technology which utilises Hyaluronic acid (HA), to deliver and enhance the retention of anti-cancer drugs within tumours. The drug becomes entrapped in a matrix of HA which binds to HA receptors located on the tumour resulting in more of the drug being delivered to the tumour cells. In preclinical studies, the HyACT(TM) technology has demonstrated improved delivery of the drug to the tumour resulting in significantly reduced toxicity and increased efficacy and survival.

About Irinotecan

Irinotecan is widely used in the treatment of metastatic colorectal cancer, and is being evaluated in many other tumour types. Like most cytotoxics the use of irinotecan is restricted by its side effects, the most significant of which are diarrhoea and neutropenia, and limited activity in some patients. Sales of Pfizer's irinotecan (Camptosar(R) ) were US$903 million in 2006, and patent exclusivity for the drug expires in 2008 in the US and 2009 in the EU.

About HyCAMP(TM)

HyCAMP(TM) is a proprietary formulation of the anti-cancer drug irinotecan. Preclinical studies with HyCAMP(TM) demonstrated improved delivery of the drug to the tumour, resulting in increased efficacy and reduced toxicity. The phase II clinical trial was initiated to evaluate HyCAMP(TM) in patients with metastatic colorectal cancer.

CLINICAL APPENDIX

The following additional information is provided in accordance with the Code of Best Practice for ASX Reporting by Life Science Companies

    Trial Title        Randomised Phase II Trial of irinotecan with Hyaluronic

                       Acid (HyCAMP(T
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
2. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
3. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
4. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
5. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
8. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
9. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
10. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
11. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
Post Your Comments:
(Date:7/1/2015)... Ill. , July 1, 2015 ... nationwide group of state and regional professional rheumatology ... survey of rheumatologists that explored perceptions of biosimilars ... on patients. Biosimilars are medicines ... biologic medicines. They are notably different from generic ...
(Date:7/1/2015)... 1, 2015 Jazz Pharmaceuticals plc (Nasdaq: JAZZ ... corporate presentation at the Cantor Fitzgerald Healthcare Conference in ... Russell Cox , executive vice president and chief ... a business and financial update on Wednesday, July 8, 2015 ... A live audio webcast of the presentation may be ...
(Date:7/1/2015)... , July 1, 2015 ContraVir Pharmaceuticals, ... on the development and commercialization of targeted antiviral therapies, ... Fitzgerald Inaugural Healthcare Conference taking place in ... at Le Parker Meridien Hotel. ... overview of the Company,s business during his live presentation ...
Breaking Medicine Technology:Survey Of Rheumatologists Nationwide Regarding Biosimilars Highlights Need For More Robust FDA Standards 2Jazz Pharmaceuticals to Present at Cantor Fitzgerald Healthcare Conference on July 8 2ContraVir to Present at Cantor Fitzgerald Inaugural Healthcare Conference 2
... 3 Glufosfamide and Phase 2 Glufosfamide Plus ... Gemcitabine Clinical Trials to be Presented, REDWOOD CITY, Calif., ... announced two presentations,regarding its oncology product candidate glufosfamide. The presentations,will ... held,September 23 to 27, 2007, at the International Conference Center ...
... First Hsp90 Inhibitor to Enter Registration Trials, HAYWARD, ... ) today announced that it has successfully,reached a binding ... the design of its TIME-1 clinical trial, a pivotal ... treatment for patients with,multiple myeloma. Through the FDA,s Special ...
Cached Medicine Technology:Threshold Pharmaceuticals Announces Two Presentations on Glufosfamide at the 2007 European Cancer Conference (ECCO) 2Threshold Pharmaceuticals Announces Two Presentations on Glufosfamide at the 2007 European Cancer Conference (ECCO) 3Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma 2Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma 3Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma 4Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma 5Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma 6Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma 7
(Date:7/1/2015)... , ... July 01, 2015 , ... ... this land of liberty. Americans have been arguing over laws governing sexuality since ... contentious period, as a forthcoming historical comparative biography by Cindy Safronoff reveals. Crossing ...
(Date:7/1/2015)... ... July 01, 2015 , ... DIC ... plant for Linablue®, Spirulina-derived natural blue food coloring. Construction of the plant, which ... U.S. Spirulina* production base, began in May 2014. After commissioning, commercial production is ...
(Date:7/1/2015)... (PRWEB) , ... July 01, 2015 , ... Summer recess ... with teenagers to fix noses and chins with plastic surgery when they’re looking for ... (ASPS) more than 236,000 cosmetic procedures were performed on patients ages 19 and younger ...
(Date:7/1/2015)... ... July 01, 2015 , ... As if mood swings, cramps and child labor ... of women: leg pain. Northeast Houston Vein Center is offering tips on the treatment ... reflux disease, is underdiagnosed and often overlooked. Many women experience the tiredness, achiness, restless ...
(Date:7/1/2015)... ... ... is a disorder in which the normally straight vertical line of the spine curves to ... the population, or an estimated 6 to 9 million people. While it is found in ... and 15. Most types of scoliosis are more common in girls than in boys. When ...
Breaking Medicine News(10 mins):Health News:Biography by Cindy Safronoff to be Released July 4 Explores an 1870s Marriage Debate Over Women’s Rights and the Implications of the American Revolution for Sexuality 2Health News:Biography by Cindy Safronoff to be Released July 4 Explores an 1870s Marriage Debate Over Women’s Rights and the Implications of the American Revolution for Sexuality 3Health News:Biography by Cindy Safronoff to be Released July 4 Explores an 1870s Marriage Debate Over Women’s Rights and the Implications of the American Revolution for Sexuality 4Health News:DIC Strengthens Its Position as the Global Leader for Natural Blue Food Coloring 2Health News:DIC Strengthens Its Position as the Global Leader for Natural Blue Food Coloring 3Health News:Top Manhattan Facial Plastic Surgeon Dr. Sam Rizk Comments on Teen Surgery Trends 2Health News:Top Manhattan Facial Plastic Surgeon Dr. Sam Rizk Comments on Teen Surgery Trends 3Health News:Northeast Houston Vein Center Offers Tips for Women with Leg Pain 2Health News:Northeast Houston Vein Center Offers Tips for Women with Leg Pain 3Health News:Scoliosis: A Guide for Parents from Orthopedic Surgeon Dr. Fabien Bitan 2Health News:Scoliosis: A Guide for Parents from Orthopedic Surgeon Dr. Fabien Bitan 3Health News:Scoliosis: A Guide for Parents from Orthopedic Surgeon Dr. Fabien Bitan 4
... Day of Fall, September 22, Focuses on Preventing ... Today Congress issued,another call to action urging government, ... prevent the increasing number of falls,among people 65 ... (D-MD),and Mike Enzi (R-WY), as well as Representatives ...
... the 2006 Medicare Current Beneficiary Survey, WASHINGTON, ... option for low and moderate income seniors and ... data from the Medicare,Current Beneficiary Survey (MCBS)., ... and those,living in rural areas, rely on Medigap ...
... Olympic Games Champion Nikki Stone and Chronic Pain ... 22 The American Society of Pain,Educators (ASPE) ... Is Your Persistent Chronic Pain Weighing You Down? ... of proper,weight control in managing chronic pain., ...
... therapy delivered in only a week , , MONDAY, Sept. ... radiosurgery may be a viable treatment for recurring pancreatic ... Center, using their precise CyberKnife to perform radiosurgery, had ... the date of treatment. The range of survival was ...
... babies. , Now, it appears how infants respond to stress ... certain gene, according to a new study from the University of ... say they have also found that good parenting as early ... counter the effect the gene has in babies who initially do ...
... Enables SPECT Procedures ... New ASNC Technology Standards, POWAY, Calif., Sept. 22 ... imaging systems and,services to physicians, offices, hospitals and other medical ... Drug,Administration (FDA) 510(k) clearance for its new nSPEED(R) reconstruction,software -- ...
Cached Medicine News:Health News:Home Safety Council(R) Applauds Creation of Falls Prevention Awareness Day 2Health News:New Webcast Going for Gold to Educate on Importance of Healthy Diet In Persistent Chronic Pain Management 2Health News:New Webcast Going for Gold to Educate on Importance of Healthy Diet In Persistent Chronic Pain Management 3Health News:New Webcast Going for Gold to Educate on Importance of Healthy Diet In Persistent Chronic Pain Management 4Health News:New Webcast Going for Gold to Educate on Importance of Healthy Diet In Persistent Chronic Pain Management 5Health News:Radiosurgery Proves Viable for Some Pancreatic Cancers 2Health News:UNC study: Parenting can override effect of genes in how babies respond to stress 2Health News:Digirad Corporation Receives FDA 510(k) Clearance for nSPEED(R) Reconstruction Software for Improved Image Quality in Less Time With Less Radiation 2Health News:Digirad Corporation Receives FDA 510(k) Clearance for nSPEED(R) Reconstruction Software for Improved Image Quality in Less Time With Less Radiation 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: